Use of whole blood as the routine transfusion product in Africa

In many countries in sub-Saharan Africa (sSA) whole blood is more commonly available from blood transfusion services than red cell concentrates. Although in recent years many countries have made significant progress in the implementing component preparation, this has largely been facilitated by external funding support. None of the sSA countries are leucocyte-reducing or irradiating blood for transfusion. Systems for the routine detection of adverse consequences of blood transfusions (hemovigilance) only exist where transfusion safety has been identified as a health priority by the government. As a resource the availability of blood transfusion in these countries is limited since less than 5 units of blood were donated per 1000 population far below the recommended requirement of 20 units/1000 per year. Young children are the main users of blood for transfusion in these sSA regions, largely due severe anaemia secondary to infection and sickle cell anaemia. Outcomes for children with severe anaemia are poor, even in those receiving a transfusion. Although it has been speculated that this may be due to transfusion-related cardiac or pulmonary events available data from observational studies and clinical trials indicates that these are rare complications of transfusion. Evidence from clinical physiology studies including those examining myocardial function before and after the receipt of whole blood provide reassuring evidence that volume overload is rare and clinical trials reporting outcomes in children receiving whole blood transfusion, including a Phase II trial examining higher volumes, indicate that there is no evidence of cardiac or pulmonary overload events